Work

From dependency to discovery

Year: 2026

Type: preprint

Abstract: An independent analysis of how the success of TNF-α inhibition shaped three decades of pharmaceutical investment in immune-mediated diseases. The paper examines the commercial legacy of the TNF-α cascade, the resulting concentration of development around a limited set of validated targets, the persistence of primary non-response in a substantial minority of patients, and the research directions left underexplored. It concludes with a discussion of the next frontier in immune-mediated disease. This is a non-peer-reviewed independent analysis.

Source: Zenodo (CERN European Organization for Nuclear Research)

DOI: 10.5281/zenodo.23976652

Author: Keraudren, pierre

Language: English

Topic: Rheumatoid Arthritis Research and Therapies

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W7225318421

Cites:

Cited by:

Related to: 10